November 22, 2018

Cancer precision medicine

Molecular testing to select targeted and conventional therapies for cancer patients is becoming standard practice. The knowledge of cancer genetics has reached a point where consensus guidelines for molecular testing cancers are emerging.

NXTGNT offers virtually all of Illumina’s fixed and custom cancer panels (external link). Illumina offers a broad portfolio of cancer panels and cancer-focused products across multiple application areas. These products have been optimized with clinical cancer research in mind. Achieve sequence-ready libraries from as little as 1 ng of high-quality input or 10 ng formalin-fixed paraffin-embedded (FFPE) sample using efficient, optimized assays and integrated sequencing and bioinformatics. Our comprehensive offering includes both fixed panels and custom options in the fields of Solid Tumor cancer,  Hematology cancer,  Germline cancer,  Pan-Cancer, Immuno-Oncology, and pan-cancer Expression Pathways.

Apart from Illumina’s cancer panels, NXTGNT specializes specifically in Massively Parallel Sequencing (MPS) liquid biopsy assays for oncology research.

EMBO Mol Med. 2015 Apr 20;7(7): 878-894